First human test for new Alpha-1 treatment begins
NCT ID NCT07193615
Summary
This is a very early study to check if a new drug called YOLT-202 is safe for people with Alpha-1 antitrypsin deficiency (AATD). It will involve 18 adults with a specific genetic form of the disease. The main goal is to find a safe dose and see how the body handles the drug over a year of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ren Ji Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, China
Conditions
Explore the condition pages connected to this study.